Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sanofi and Denali Reach Potential $1+ Billion Deal

Denali announced a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases that could be worth more than $1 billion.

Read More »

Eli Lilly, Dicerna Reach RNAi Therapies Deal

Dicerna Pharmaceuticals and Eli Lilly struck a deal to use an RNAi technology platform for up to 10 cardio-metabolic, neurodegeneration and pain targets.

Read More »

Novo Nordisk hires AstraZeneca executive

Novo Nordisk is in advanced talks to acquire assets to bolster the company’s struggling biopharma business after the drugmaker announced the hiring of an AstraZeneca executive to head the unit.

Read More »

SQZ, Roche reach expansion deal of up to $1 billion

Watertown, Mass.-based SQZ Biotechnologies could be on the receiving end of up to $1 billion following the company’s signing of an expansion agreement with pharma giant Roche.

Read More »

Up-and-Coming Automation Company Berkeley Lights Raises $95 Million

Emeryville, Calif.-based Berkeley Lights closed on a $95 million financing round, led by Nikon.

Read More »

Ionis and Roche agree on dry AMD treatment deal

Ionis Pharmaceuticals inked a deal worth more than $700 million with pharma giant Roche to develop an antisense drug for the treatment of complement-mediated diseases.

Read More »

J&J, Arrowhead reach gene-silencing drug deal

J&J agreed to develop and market Arrowhead Pharmaceuticals Inc.’s gene-silencing hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion.

Read More »

Boston Pharma Doubles Pipeline with 2 Deals with Novartis and GSK

Boston Pharmaceuticals licenses a slew of compounds from GlaxoSmithKline and Novartis in two separate deals.

Read More »

Five-Member GO Therapeutics Inks Deal with Roche

GO Therapeutics, with headquarters in Cambridge, Mass., signed a licensing deal with Swiss-based Roche to develop antibodies for cancer.

Read More »

Janssen Terminates Collaboration with Aduro Biotech

Janssen Biotech informed Aduro Biotech that the Johnson & Johnson company was terminating a research and license deal related to Aduro’s Listeria treatment for cancers.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom